Donidalorsen (IONIS-PKK-LRx)
Hereditary Angioedema (HAE)
Phase 3Active
Key Facts
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a commercial-stage biotech leader with a mission to discover and deliver life-changing RNA-targeted medicines. The company has achieved multiple industry firsts, including the first approved antisense drug, and has successfully transitioned from a research-focused entity to a fully integrated organization with its own commercial capabilities. Its strategy centers on independently launching medicines in neurology and cardiology while selectively partnering in other areas, backed by a deep, late-stage pipeline and a sustainable technology platform.
View full company profileTherapeutic Areas
Other Hereditary Angioedema (HAE) Drugs
| Drug | Company | Phase |
|---|---|---|
| HAE Treatment | Cycle Pharmaceuticals | Commercial |
| NTLA-2002 (lonvoguran ziclumeran) | Intellia Therapeutics | Phase 3 |